The introduction of disease-modifying therapies for Alzheimers disease (AD) can be an urgent issue. avoidance Rabbit Polyclonal to TPH2 (phospho-Ser19) could be essential to the achievement of disease adjustment. imaging techniques, position (“type”:”clinical-trial”,”attrs”:”text message”:”NCT00575055″,”term_id”:”NCT00575055″NCT00575055 and “type”:”clinical-trial”,”attrs”:”text message”:”NCT00574132″,”term_id”:”NCT00574132″NCT00574132). Nevertheless, clinical advancement of bapineuzumab was terminated in Aug. 2012 as the initial two stage 3 clinical studies… Continue reading The introduction of disease-modifying therapies for Alzheimers disease (AD) can be